CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 17996 [2017-07593]

Download as PDF 17996 Federal Register / Vol. 82, No. 71 / Friday, April 14, 2017 / Notices sradovich on DSK3GMQ082PROD with NOTICES Conducting Public Health Research in South Africa; GH17–004, Conducting Public Health Research Activities in Egypt. Summary: This publication corrects a notice that was published in the Federal Register on April 4, 2017, Volume 82, Number 63, page 16403. The meeting announcement, meeting date, and matters for discussion should read as follows: The meeting announced below concerns the Centers for Disease Control and Prevention (CDC) initial review of applications in response to Funding Opportunity Announcements GH17– 002, Program Development and Research to Establish and Evaluate Innovative and Emerging Best Practices in Clinical and Community Services through the President’s Emergency Plan for AIDS Relief (PEPFAR); and GH17– 003, Conducting Public Health Research in South Africa. Time and Date: 9:00 a.m.–2:00 p.m., EDT, April 25, 2017, Panel A (Closed). Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Program Development and Research to Establish and Evaluate Innovative and Emerging Best Practices in Clinical and Community Services through the President’s Emergency Plan for AIDS Relief (PEPFAR)’’, FOA GH17–002; and ‘‘Conducting Public Health Research in South Africa’’, FOA GH17–003. For Further Information Contact: Hylan Shoob, Scientific Review Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600 Clifton Road NE., Mailstop D–69, Atlanta, Georgia 30033, Telephone: (404) 639–4796, HSHOOB@CDC.GOV. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–07595 Filed 4–13–17; 8:45 am] BILLING CODE 4163–18–P VerDate Sep<11>2014 16:21 Apr 13, 2017 Jkt 241001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Health Resources and Services Administration CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration (HRSA) announce the following committee meeting. Times and Dates: 8:30 a.m.–5:00 p.m., EDT, May 10, 2017; 8:30 a.m.–3:00 p.m., EDT, May 11, 2017. Place: CDC Corporate Square, Building 8, Conference Room 1–ABC, 8 Corporate Boulevard, Atlanta, Georgia 30329, Telephone: (404) 639–8317. The meeting is also accessible by teleconference. Toll-free number 1–877– 603–4228, Participant code: 42598858. Status: Open to the public, limited only by the space available. The meeting room will accommodate approximately 100 people. Persons who desire to make an oral statement, may request it at the time of the public comment period on May 10, 2017 at 4:30 p.m., EDT. Public participation and ability to comment will be limited to space and time as it permits. Purpose: This committee is charged with advising the Director, CDC and the Administrator, HRSA, regarding activities related to prevention and control of HIV/AIDS, Viral Hepatitis and other STDs, the support of health care services to persons living with HIV/ AIDS, and education of health professionals and the public about HIV/ AIDS, Viral Hepatitis and other STDs. Matters for Discussion: Agenda items include the following topics: (1) HIV transmission risk in the context of viral suppression and antiretroviral therapy (ART) use; (2) Update on Pre-Exposure Prophylaxis (PrEP) utilization; (3) Vulnerable youth at risk for HIV, STDs, hepatitis, substance use and other health outcomes; (4) Eliminating hepatitis B and hepatitis C as public health threats in the United States— Setting Goals and Taking Action; and (5) Updates from Workgroups. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Margie Scott-Cseh, Centers for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop E–07, Atlanta, PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 Georgia 30329, telephone (404) 639– 8317; Email: zkr7@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–07593 Filed 4–13–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Healthcare Infection Control Practices Advisory Committee (HICPAC) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) announces a meeting of the aforementioned committee: Time and Date: 1:00 p.m.–2:30 p.m., EDT, May 5, 2017. Place: This meeting will be accessible by teleconference. Toll-free +1 (888) 469–1070, Participant Code: 3132529. Status: Open to the public limited only by the availability of 200 telephone ports. To register for this call, please go to www.cdc.gov/hicpac. Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, the Secretary, Health and Human Services regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions. Matters for Discussion: The agenda will include a follow-up discussion on the Draft Recommendation Update for Chlorhexidine Impregnated Dressings. Call materials will be made available to the public no later than 2 business days E:\FR\FM\14APN1.SGM 14APN1

Agencies

[Federal Register Volume 82, Number 71 (Friday, April 14, 2017)]
[Notices]
[Page 17996]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07593]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Health Resources and Services Administration


CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD 
Prevention and Treatment

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) and the Health Resources and Services Administration 
(HRSA) announce the following committee meeting.

    Times and Dates: 8:30 a.m.-5:00 p.m., EDT, May 10, 2017; 8:30 a.m.-
3:00 p.m., EDT, May 11, 2017.
    Place: CDC Corporate Square, Building 8, Conference Room 1-ABC, 8 
Corporate Boulevard, Atlanta, Georgia 30329, Telephone: (404) 639-8317. 
The meeting is also accessible by teleconference. Toll-free number 1-
877-603-4228, Participant code: 42598858.
    Status: Open to the public, limited only by the space available. 
The meeting room will accommodate approximately 100 people. Persons who 
desire to make an oral statement, may request it at the time of the 
public comment period on May 10, 2017 at 4:30 p.m., EDT. Public 
participation and ability to comment will be limited to space and time 
as it permits.
    Purpose: This committee is charged with advising the Director, CDC 
and the Administrator, HRSA, regarding activities related to prevention 
and control of HIV/AIDS, Viral Hepatitis and other STDs, the support of 
health care services to persons living with HIV/AIDS, and education of 
health professionals and the public about HIV/AIDS, Viral Hepatitis and 
other STDs.
    Matters for Discussion: Agenda items include the following topics: 
(1) HIV transmission risk in the context of viral suppression and 
antiretroviral therapy (ART) use; (2) Update on Pre-Exposure 
Prophylaxis (PrEP) utilization; (3) Vulnerable youth at risk for HIV, 
STDs, hepatitis, substance use and other health outcomes; (4) 
Eliminating hepatitis B and hepatitis C as public health threats in the 
United States--Setting Goals and Taking Action; and (5) Updates from 
Workgroups. Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Margie Scott-Cseh, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE., Mailstop E-07, 
Atlanta, Georgia 30329, telephone (404) 639-8317; Email: zkr7@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2017-07593 Filed 4-13-17; 8:45 am]
BILLING CODE 4163-18-P